
    
      Up to 150 subjects having a diagnosis of active plaque psoriasis and fulfilling the study
      eligibility criteria were enrolled in Mexico. Adalimumab was administered as follows: 80 mg
      at baseline, followed by 40 mg every other week (eow; starting at week 1 until week 15). The
      study drug was self administered via subcutaneous (sc) injection. Safety and efficacy
      measures were performed throughout the study.
    
  